Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12650870 | 1.00 | MAOA (0.39) | MAOAMAOBOPRM1OPRK1MEN1 | |
| SCHEMBL13693198 | 0.84 | DPP8 (0.39) | MAOAMAOBOPRM1MEN1KMT2A | |
| SCHEMBL13181522 | 0.83 | MAOA (0.38) | MAOAMAOBOPRM1OPRL1ACE | |
| SCHEMBL4737676 | 0.79 | MEN1 (0.36) | MAOAMAOBOPRM1OPRK1MEN1 | |
| SCHEMBL13247993 | 0.79 | MEN1 (0.36) | MAOAMAOBOPRM1OPRK1MEN1 | |
| SCHEMBL12658781 | 0.77 | MEN1 (0.38) | MEN1KMT2AACE | |
| SCHEMBL21323509 | 0.77 | MEN1 (0.34) | MAOAMAOBOPRM1OPRK1MEN1 | |
| SCHEMBL22525290 | 0.77 | MEN1 (0.34) | MAOAMAOBOPRM1OPRK1MEN1 | |
| SCHEMBL12658784 | 0.77 | MEN1 (0.38) | MEN1KMT2AACE | |
| SCHEMBL12658783 | 0.77 | MEN1 (0.38) | MEN1KMT2AACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | MAOA 688/4885MAOB 499/4885OPRM1 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.